| 1. |
- Abrahamsson, Per-Anders
(author)
-
Prostate cancer and active surveillance.
- 2008
-
In: Frontiers of Radiation Therapy and Oncology. - Basel : KARGER. - 0071-9676. ; 41, s. 41280-41280
-
Journal article (peer-reviewed)abstract
- This review outlines the different treatment options in localized prostate cancer. This information can be considered alongside other important factors, such as the individual patient's values and situation as well as the potential impact of treatment on his quality of life, in the treatment decision-making process. Taking all these factors into consideration, the data support active surveillance as an appropriate choice in patients with well or moderately differentiated, low-volume prostate cancer who have a life expectancy of less than 10 years. Men with higher-grade tumors and longer life expectancy may be at excess risk of death from prostate cancer managed with active surveillance.
|
|
| 2. |
|
|
| 3. |
- Micke, O., et al.
(author)
-
Complementary and alternative medicine in lung cancer patients : a neglected phenomenon?
- 2010
-
In: Frontiers of radiation therapy and oncology. - : S. Karger AG. - 0071-9676 .- 1662-3789. ; 42, s. 198-205
-
Journal article (peer-reviewed)abstract
- Study on the use of complementary and alternative medicine (CAM) in lung cancer patients has been widely neglected. Therefore, we initiated a study on the use of CAM in lung cancer patients in addition to radiation treatment. Overall, 120 patients from 3 institutions were interviewed by a standardized questionnaire. Besides the tumor parameters and the use of CAM, the reason for the use, patient information of the medication, the information sources and the subjective condition of the patient. Altogether, 54% of the patients reported using CAM (66% of female patients, 52% of male patients). The most frequently used CAM measures were vitamin combinations (17%), mistletoe (15%), and selenium (12%). A total of 52% reported the wish to support the tumor treatment as a reason for using CAM and 27% had a 'better feeling' using CAM. 50% of CAM was bought by the patients themselves and 50% were prescribed by their family physicians. The use of CAM is frequent in lung cancer patients. Our results suggest that it is very important to obtain information on the CAM use of patients and, particularly in controlled clinical trials, to prospectively document it.
|
|
